Search hospitals > Virginia > Richmond
Novartis Investigative Site
Claim this profileRichmond, Virginia 23226
Global Leader in Chronic Obstructive Pulmonary Disease
Global Leader in Obstructive Lung Diseases
Conducts research for Lung Disease
Conducts research for COVID-19
Conducts research for Atopic Dermatitis
145 reported clinical trials
6 medical researchers
Summary
Novartis Investigative Site is a medical facility located in Richmond, Virginia. This center is recognized for care of Chronic Obstructive Pulmonary Disease, Obstructive Lung Diseases, Lung Disease, COVID-19, Atopic Dermatitis and other specialties. Novartis Investigative Site is involved with conducting 145 clinical trials across 116 conditions. There are 6 research doctors associated with this hospital, such as Omer Khalid, Kara Foster-Weiss, Call, Robert, and Leroy Vaughan.Top PIs
Omer KhalidGI Select Health Research, LLC4 years of reported clinical research
Studies Non-alcoholic Fatty Liver Disease
Studies Nonalcoholic Steatohepatitis
3 reported clinical trials
5 drugs studied
Kara Foster-WeissClinical Research Partners, LLC4 years of reported clinical research
Studies Crohn's Disease
2 reported clinical trials
1 drug studied
Call, RobertClinical Research Partners, LLC2 years of reported clinical research
Studies Celiac Disease
1 reported clinical trial
1 drug studied
Leroy VaughanClinical Research Partners1 year of reported clinical research
Studies COVID-19
Studies Coronavirus
1 reported clinical trial
3 drugs studied
Clinical Trials running at Novartis Investigative Site
COVID-19
Crohn's Disease
Atopic Dermatitis
Gout
Sleep Disorders
Celiac Disease
Eczema
Flu
Acute Coronary Syndrome
Syndrome
mRNA-1273.214 Vaccine
for COVID-19 in Children
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of the mRNA-1273.815 vaccine, when administered as a BD in participants aged 6 months to <6 years (Part 3) and when administered to SARS-CoV-2 vaccine-naïve participants aged 2 years to <5 years of age (Part 4).
Recruiting3 awards Phase 3
S-217622
for COVID-19
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Recruiting1 award Phase 312 criteria
mRNA-1273.214 Vaccine
for Infant COVID-19
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in Richmond, Virginia. This center is recognized for care of Chronic Obstructive Pulmonary Disease, Obstructive Lung Diseases, Lung Disease, COVID-19, Atopic Dermatitis and other specialties. Novartis Investigative Site is involved with conducting 145 clinical trials across 116 conditions. There are 6 research doctors associated with this hospital, such as Omer Khalid, Kara Foster-Weiss, Call, Robert, and Leroy Vaughan.